Improvement in Patient-Reported Emotional Symptoms and Activity Limitations Due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO-2b/3

October 2025 in “ International Journal of Dermatology ”

Ernest H. Law, Bintu Sherif, Arash Mostaghimi, Brett King, Rodney Sinclair, Natasha Atanaskova Mesinkovska, Kent A. Hanson, Dane Korver, Costel Chirila

alopecia areata ritlecitinib

This study, part of the ALLEGRO-2b/3 trial, evaluated the impact of ritlecitinib on emotional symptoms and activity limitations in 325 patients with alopecia areata. By Week 48, those on a 50-mg dose of ritlecitinib showed significantly greater improvements in emotional symptoms, such as self-consciousness and embarrassment, and in activity limitations, particularly in outdoor activities and exercise, compared to those on a 10-mg dose. The findings suggest that ritlecitinib can alleviate the psychosocial burden associated with hair loss in alopecia areata patients, enhancing their quality of life, although longer follow-up may be needed to observe full benefits.

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Research cited in this study

14 / 14 results

research European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata

4 citations , January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.

research Ritlecitinib: First Approval

84 citations , August 2023 in “Drugs”

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

research Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial

227 citations , April 2023 in “The Lancet”

research Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs

1 citations , March 2023 in “Clinical, Cosmetic and Investigational Dermatology”

Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.

research The Burden of Alopecia Areata: A Scoping Review Focusing on Quality of Life, Mental Health, and Work Productivity

10 citations , January 2023 in “Journal of the European Academy of Dermatology and Venereology”

Alopecia areata greatly affects people's life quality, mental health, and work life.

research The Association of Alopecia Areata-Related Emotional Symptoms with Work Productivity and Daily Activity Among Patients with Alopecia Areata

29 citations , December 2022 in “Dermatology and Therapy”

Emotional symptoms from alopecia areata reduce work productivity and daily activity.

research Integrated Safety Analysis of Baricitinib in Adults With Severe Alopecia Areata From Two Randomized Clinical Trials

25 citations , November 2022 in “British journal of dermatology/British journal of dermatology, Supplement”

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

research Two Phase 3 Trials of Baricitinib for Alopecia Areata

148 citations , March 2022 in “The New England Journal of Medicine”

Baricitinib was effective in treating alopecia areata in two major trials.

research Validation of the Alopecia Areata Patient Priority Outcomes Questionnaire in Adults and Adolescents with Alopecia Areata

22 citations , November 2021 in “Dermatology and Therapy”

The AAPPO questionnaire is a reliable tool for assessing hair loss impact in alopecia areata patients.

research Patient Perspectives of the Social, Emotional and Functional Impact of Alopecia Areata: A Systematic Literature Review

67 citations , March 2021 in “Dermatology and Therapy”

Alopecia areata greatly harms quality of life, causing emotional and social issues.

research Evaluation of Stigma Toward Individuals With Alopecia

38 citations , March 2021 in “JAMA Dermatology”

People often have negative attitudes toward those with alopecia, especially if it's severe or seen as a medical issue.

research Development of the Alopecia Areata Patient Priority Outcomes Instrument: A Qualitative Study

11 citations , March 2021 in “Dermatology and therapy”

Researchers created a new tool to measure the effects of alopecia areata from the patient's view, focusing on hair loss, daily life, and emotional health.

research Alopecia Areata: Overview and Insights from January 2018

290 citations , December 2017 in “Journal of The American Academy of Dermatology”

Alopecia areata is an autoimmune condition causing hair loss, influenced by genetics, stress, and diet, and may be prevented by a high soy oil diet.

research Alopecia Areata: An Autoimmune Disease Causing Hair Loss

421 citations , April 2012 in “The New England Journal of Medicine”

Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.

Similar Research

6 / 1000+ results

research Alopecia Areata and Ritlecitinib: Unraveling Response Trajectories

May 2025 in “Journal of the European Academy of Dermatology and Venereology”

Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.

research Unravelling The Role Of JAK3/TEC Kinase Signalling With Ritlecitinib In Alopecia Areata Lesional Skin And Alopecia Areata-Induced Human Hair Follicles Ex Vivo

July 2025 in “Journal of Investigative Dermatology”

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

research Ritlecitinib: First Approval

84 citations , August 2023 in “Drugs”

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

research A Concise Review on Novel Drugs Applied in Treatment of Alopecia

February 2025

New therapies like JAK inhibitors, PRP, and stem cell treatments show promise for better alopecia management.

research Patterns of Clinical Response in Patients With Alopecia Areata Treated With Ritlecitinib in the Allegro Clinical Development Programme

13 citations , February 2025 in “Journal of the European Academy of Dermatology and Venereology”

research Exploring Novel Management Options for Alopecia Areata

March 2026 in “The American Journal of Managed Care”

JAK inhibitors can help treat alopecia areata but have risks and high costs.

Improvement in Patient-Reported Emotional Symptoms and Activity Limitations Due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO-2b/3

Research cited in this study

research European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata

research Ritlecitinib: First Approval

research Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial

research Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs

research The Burden of Alopecia Areata: A Scoping Review Focusing on Quality of Life, Mental Health, and Work Productivity

research The Association of Alopecia Areata-Related Emotional Symptoms with Work Productivity and Daily Activity Among Patients with Alopecia Areata

research Integrated Safety Analysis of Baricitinib in Adults With Severe Alopecia Areata From Two Randomized Clinical Trials

research Two Phase 3 Trials of Baricitinib for Alopecia Areata

research Validation of the Alopecia Areata Patient Priority Outcomes Questionnaire in Adults and Adolescents with Alopecia Areata

research Patient Perspectives of the Social, Emotional and Functional Impact of Alopecia Areata: A Systematic Literature Review

research Evaluation of Stigma Toward Individuals With Alopecia

research Development of the Alopecia Areata Patient Priority Outcomes Instrument: A Qualitative Study

research Alopecia Areata: Overview and Insights from January 2018

research Alopecia Areata: An Autoimmune Disease Causing Hair Loss

Related Community Posts Join

community Anyone else taking Litfulo (ritlecitinib) to treat their alopecia?

community Article of all potential future cures

community Well here I am 3-4 years later.

community Topical Finasteride reduced my DHT more than Oral Dutasteride

community I 24F have gone from a full head of hair to ~30% of hair in 2 weeks

community Please stop looking for a natural way to stop your hairloss

Similar Research

research Alopecia Areata and Ritlecitinib: Unraveling Response Trajectories

research Unravelling The Role Of JAK3/TEC Kinase Signalling With Ritlecitinib In Alopecia Areata Lesional Skin And Alopecia Areata-Induced Human Hair Follicles Ex Vivo

research Ritlecitinib: First Approval

research A Concise Review on Novel Drugs Applied in Treatment of Alopecia

research Patterns of Clinical Response in Patients With Alopecia Areata Treated With Ritlecitinib in the Allegro Clinical Development Programme

research Exploring Novel Management Options for Alopecia Areata